

	<u>Q1 2023</u>	<u>Q2 2023</u>	<u>Actual</u>			<u>FY 2023</u>	<u>FY 2024 Outlook</u>	
			<u>Q3 2023</u>	<u>Q4 2023</u>			<u>Low</u>	<u>High</u>
<b>Revenue</b>								
Medicare Advantage & Other	\$407	\$432	\$426	\$434.118		\$1,700		
ACO REACH	\$32	\$30	\$30	\$31		\$124		
Total Revenue	\$439	\$462	\$457	\$465		\$1,824	\$2,380	\$2,410
<b>Adjusted Gross Profit <sup>(1)</sup></b>								
Medicare Advantage & Other	\$43	\$56	\$61	\$52		\$212		
ACO REACH	\$3	(\$2)	(\$0)	(\$3)		(\$3)		
Total Adjusted Gross Profit	\$45	\$54	\$61	\$49		\$209	\$275	\$310
<b>MBR (%)</b>								
Medicare Advantage & Other	89.5%	87.1%	85.7%	88.0%		87.6%		
ACO REACH	92.0%	107.7%	100.6%	108.8%		102.2%		
Total MBR (%)	89.7%	88.4%	86.7%	89.4%		88.5%		
<b>Adjusted SG&amp;A <sup>(2)</sup></b>								
Adjusted SG&A	\$51	\$56	\$69	\$69		\$244		
% of Revenue Excluding ACO REACH	12.4%	12.9%	16.2%	15.9%		14.4%		
% of Total Revenue	11.5%	12.0%	15.1%	14.8%		13.4%		
<b>Adjusted EBITDA <sup>(3)</sup></b>								
Adjusted EBITDA	(\$5)	(\$2)	(\$8)	(\$20)		(\$35)	(\$15)	\$15

(1) Adjusted gross profit is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as loss from operations before depreciation and amortization, clinical equity-based compensation expense, and selling, general, and administrative expenses. We cannot reconcile our estimated ranges for adjusted gross profit to loss from operations, the most directly comparable GAAP measure, and cannot provide estimated ranges for loss from operations, without unreasonable efforts because of the uncertainty around certain items that may impact loss from operations, including equity-based compensation expense and depreciation and amortization, that are not within our control or cannot be reasonably predicted.

(2) Adjusted SG&A is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as the difference between adjusted EBITDA and adjusted gross profit. We cannot reconcile our estimated ranges for adjusted SG&A to selling, general and administrative expenses, the most directly comparable GAAP measure, and cannot provide estimated ranges for selling, general and administrative expenses, without unreasonable efforts because of the uncertainty around certain items that may impact loss from operations, including equity-based compensation expense and depreciation and amortization, that are not within our control or cannot be reasonably predicted.

(3) Adjusted EBITDA is a non-GAAP financial measure that is presented as supplemental disclosure, that we define as net loss before interest expense, income taxes, depreciation and amortization expense, transaction-related expenses, acquisition expenses, certain litigation costs and settlements, gains or losses on ROU assets, equity-based compensation expense, and loss on extinguishment of debt. We cannot reconcile our estimated ranges for Adjusted EBITDA to net loss, the most directly comparable GAAP measure, and cannot provide estimated ranges for net loss, without unreasonable efforts because of the uncertainty around certain items that may impact net loss, including equity-based compensation expense and depreciation and amortization, that are not within our control or cannot be reasonably predicted.